

Results of Extraordinary General Meeting

Bluechiip Limited (**Bluechiip** or the **Company**) (**ASX: BCT**), a leader in the development of advanced sample management solutions for harsh environments, is pleased to announce the results of today's Extraordinary General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001.

All resolutions were passed and decided by the way of a poll.

END.

Authorised for release by the Bluechiip Limited Board

For more information, please contact:

Corporate enquiries

Andrew McLellan
Managing Director / CEO
Ph: +61 457 823 470
andrew.mclellan@bluechiip.com

Media

Richard Allen
Ph: +61 403 493 049
Oxygen Financial PR
richard@oxygenpr.com.au

About Bluechiip Limited

Bluechiip understands that every biological sample – stem cells, blood, eggs, sperm and other biospecimens – is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced sample management solution is the only one that provides sample temperature with ID in cryogenic environments, driving productivity and improving quality. Bluechiip's solution delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product is easily identified and critical information, such as sample temperature, detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip[®] Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip listed on the ASX in June 2011. Since then, we have significantly developed our technology. Today it has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

Further information is available at www.bluechiip.com

Disclosure of Proxy Votes

Bluechiip Limited

Extraordinary General Meeting

Thursday, 29 August 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of prior issue of 119,306,069 Shares pursuant to the February Private Placement	P	403,399,687	378,652,937 93.87%	417,814 0.10%	4,192,778	24,328,936 6.03%	430,080,444 94.70%	24,078,415 5.30%	6,542,778	Passed
2 Ratification of prior issue of 81,272,726 Shares pursuant to the June Private Placement	P	436,587,436	411,420,686 94.24%	837,814 0.19%	4,089,921	24,328,936 5.57%	462,848,193 94.97%	24,498,415 5.03%	6,439,921	Passed
3 Approval of issue of Shares to related party, Michael Ohanessian, Non-Executive Director pursuant to the June Placement	P	441,507,942	416,437,864 94.32%	741,142 0.17%	1,442,142	24,328,936 5.51%	448,599,865 94.84%	24,401,743 5.16%	3,792,142	Passed
4 Approval of future issue of Convertible Notes	P	442,125,084	412,958,336 93.40%	4,837,812 1.09%	825,000	24,328,936 5.50%	464,385,843 94.22%	28,498,413 5.78%	3,175,000	Passed
5 Approval of issue of Shares to Andrew McLellan, CEO and Managing Director	P	430,994,614	403,273,900 93.57%	3,391,778 0.79%	1,339,285	24,328,936 5.64%	451,221,051 94.34%	27,052,379 5.66%	3,689,285	Passed
6 Approval of issue of Shares to Directors in lieu of directors' fees	P	383,347,340	328,301,968 85.64%	30,816,436 8.04%	925,000	24,228,936 6.32%	338,411,205 86.13%	54,477,037 13.87%	3,275,000	Passed

